ImmunoGenesis Doses First Patient in Clinical Trial of Drug for Advanced Solid Tumors Sep 28 Written by Mukul Verma ImmunoGenesisCFF Mukul Verma Previous Previous Cancer Focus Fund invests $4.8M into Houston-based March Biosciences (Houston Business Journal) Next Next Houston Oncology Summit: MD Anderson’s Ferran Prat, VP of industry relations, talks about partnering
ImmunoGenesis Doses First Patient in Clinical Trial of Drug for Advanced Solid Tumors Sep 28 Written by Mukul Verma ImmunoGenesisCFF Mukul Verma
